Skip to content

Effect of acetaminophen mannitol injection on postoperative pain in thoracoscopic lung cancer patients

Effect of acetaminophen mannitol injection on postoperative pain in thoracoscopic lung cancer patients - none

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072623
Enrollment
Unknown
Registered
2023-06-19
Start date
2023-06-15
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracoscopic postoperative analgesia

Interventions

Group D (acetaminophen mannitol injection) and Group S (flurbiprofen exate injection):Group D: Intravenous infusion of 500 mg acetaminophen mannitol injection before single lung ventilation
Group S (flurbiprofen exate injection):Group S: Intravenous infusion of 50 mg flurbiprofen axidate injection before single lung ventilation.

Sponsors

the First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. 18= age =65 years old, gender is not limited; 2. Elective surgery; 3. ASA score is Level I or Level II; 4. 18 kg/m2 < BMI < 30kg/m2; 5. Clearly understand and voluntarily participate in the study, and have their informed consent signed;

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Uncontrolled hypertension and diabetes; (2) liver and kidney function exceeds normal value; (3) Patients with mental system diseases and long-term history of taking psychiatric drugs and cognitive impairment; (4) Pregnant or lactating women; (5) People allergic to acetaminophen, opioids, propofol, muscle pine and other drugs; (6) Other circumstances in which the investigator considers it inappropriate to participate in the experiment;

Design outcomes

Primary

MeasureTime frame
VAS;blood pressure;

Secondary

MeasureTime frame
heart rate;Choking cough;Extubation time;Adverse reactions;

Countries

China

Contacts

Public Contactjinwenjie

Jiangsu Province Hospital

1578852260@qq.com+86 132 7516 9723

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026